US20060239959A1 - Method for treating hypercholesterolemia with polyallylamine polymers - Google Patents

Method for treating hypercholesterolemia with polyallylamine polymers Download PDF

Info

Publication number
US20060239959A1
US20060239959A1 US11/344,862 US34486206A US2006239959A1 US 20060239959 A1 US20060239959 A1 US 20060239959A1 US 34486206 A US34486206 A US 34486206A US 2006239959 A1 US2006239959 A1 US 2006239959A1
Authority
US
United States
Prior art keywords
solid
polymer
patient
water
crosslinking agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/344,862
Inventor
Stephen Holmes-Farley
W. Mandeville
Steven Burke
Dennis Goldberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US11/344,862 priority Critical patent/US20060239959A1/en
Publication of US20060239959A1 publication Critical patent/US20060239959A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • One method of reducing the amount of bile acids that are reabsorbed and, thus, reducing serum cholesterol is the oral administration of compounds that sequester the bile acids and cannot themselves be absorbed. The sequestered bile acids consequently are excreted.
  • bile acid sequestration examples include various ion exchange polymers.
  • One such polymer is cholestyramine, a copolymer of divinylbenzene/styrene and trimethylammonium methylstyrene. It has been long recognized that this polymer is unpalatable, gritty, and constipating. More recently, various polymers have been suggested which are characterized by hydrophobic substituents and quaternary ammonium radicals substituted upon an amine polymer backbone (Ahlers, et al. U.S. Pat. Nos. 5,428,112 and 5,430,110 and McTaggert, et al., U.S. Pat. No. 5,462,730, which are incorporated herein by reference).
  • the invention relates to the unexpected discovery that a new class of ion exchange resins have improved bile salt sequestration properties resulting in reduced dosages, which improve patient tolerance and compliance, thereby improving the palatability of the composition and are relatively easy to manufacture.
  • the polymers, employed in the invention comprise non-absorbable, and optionally cross-linked polyamines as defined herein. The properties of the polymer which gave rise to the present invention were discovered during clinical trials of the polymer for its use in binding phosphate in patients suffering from hyperphosphatemia.
  • the polyamines of the invention are characterized by one or more monomeric units of the formula: and salts thereof, where n is a positive integer and x is 0 or an integer between 1 and about 4.
  • the polymer can be characterized by the substantial absence of one or more alkylated amine monomers and/or the substantial absence of one or-more trialkylammonium alkyl groups.
  • the polymer is crosslinked by means of a multifunctional crosslinking agent.
  • the invention provides an effective treatment for removing bile salts from a patient (and thereby reducing the patient's cholesterol level), particularly in patients with a serum LDL level of at least about 130 mg/dL.
  • the invention also provides for the use of the polymers described herein for the manufacture of a medicament for the treatment of hypercholesterolemia or for bile acid sequestration.
  • the Figure presents the effect of cross-linked polyallylamine on LDL cholesterol relative to baseline LDL cholesterol.
  • the polymers employed in the invention comprise, optionally cross-linked polyamines characterized by the formula above.
  • Preferred polymers are polyallylamine or polyvinylamine.
  • the polymers can be characterized by the substantial absence of substituted or unsubstituted alkyl substituents on the amino group of the monomer, such as obtained in the alkylation of an amine polymer. That is, the polymer can be characterized in that the polymer is substantially free of alkylated amine monomers.
  • the polymer can be a homopolymer or a copolymer of one or more amine-containing monomers or non-amine containing monomers. Where copolymers are manufactured with the monomer of the above formula, the comonomers are preferably inert, non-toxic and/or possess bile acid sequestration properties. Examples-of suitable non-amine-containing monomers include vinylalcohol, acrylic acid, acrylamide, and vinylformamide. Examples of amine containing monomers preferably include monomers having the Formula 1 above.
  • the monomers are aliphatic.
  • the polymer is a homopolymer, such as a homopolyallylamine or homopolyvinylamine.
  • the polymer is rendered water-insoluble by crosslinking.
  • the cross-linking agent can be characterized by functional groups which react with the amino group of the monomer.
  • the crosslinking group can be characterized by two ore more vinyl groups which undergo free radical-polymerization with the amine monomer.
  • crosslinking agents examples include acryloyl chloride, epichlorohydrin, butanedioldiglycidyl ether, ethanedioldiglycidyl ether, and dimethyl succinate.
  • a preferred crosslinking agent is epichlorohydrin because of its high availability and low cost.
  • Epichlorohydrin is also advantageous because of it's low molecular weight and hydrophilic nature, maintaining the water-swellability of the polyamine gel.
  • the level of crosslinking makes the polymers insoluble and substantially resistant to absorption and degradation, thereby limiting the activity of the polymer to the gastrointestinal tract.
  • the compositions are non-systemic in their activity and will lead to reduced side-effects in the patient.
  • the cross-linking agent is present in an amount from about 0.5-25% (more preferably about 2.5-20% and most preferably 1-10%). by weight, based upon total weight of monomer plus crosslinking agent.
  • the amount of crosslinking-agent that is reacted with the amine polymer is sufficient to cause between about 0.5 and twenty percent of the amines. In a preferred embodiment, between about 0.5 and 20 percent of the amine groups react with the crosslinking agent.
  • Preferred polymers of the invention are generally known in the art. Holmes-Farley, et al. (U.S. Pat. No. 5,496,545), describes the use of aliphatic amine polymers in the treatment of hyperphosphatemia. These polymers have also been suggested for use in the treatment of iron-overload (Mandeville, et al., U.S. Pat. No. 5,487,888). The teachings of both of these patents are incorporated herein by reference.
  • Non-cross-linked and cross-linked polyallylamine and polyvinylamine are generally known in the art and/or are commercially available. Methods for the manufacture of polyallylamine and polyvinylamine, and cross-linked derivatives thereof, are described in the above US Patents, the teachings of which are incorporated entirely by reference. Harada et al. (U.S. Pat. Nos. 4,605,701 and 4,528,347, which are incorporated herein by reference in their entirety) also describe methods of manufacturing polyallylamine and cross-linked polyallylamine.
  • the polymer can be administered in the form of a salt.
  • salt it is meant that the nitrogen group in the repeat unit is protonated to create a positively charged nitrogen atom associated with a negatively charged counterion.
  • the cationic counterions can be selected to minimize adverse effects on the patient, as is more particularly described below.
  • suitable counterions include Cl ⁇ , Br ⁇ , CH 3 OSO 3 ⁇ , HSO 4 ⁇ , SO 4 2 ⁇ , HCO 3 ⁇ , CO 3 ⁇ , acetate, lactate, succinate, propionate, butyrate, ascorbate, citrate, maleate, folate, an amino acid derivative, a nucleotide, a lipid, or a phospholipid.
  • the counterions can be the same as, or different from, each other.
  • the reaction product can contain two different types of counterions, both of which are exchanged for the bile salts being removed.
  • the polymers according to the invention can be administered orally to a patient in a dosage of about 1 mg/kg/day to about 1 g/kg/day, preferably between about 5 mg/kg/day to about 200 mg/kg/day (such as between about 10 mg/kg/day to about 200 mg/kg/day); the particular dosage will depend on the individual-patient (e.g., the patient's weight and the extent of bile salt removal required).
  • the polymer can be administrated either in hydrated or dehydrated form, and can be flavored or added to a food or drink, if desired to enhance patient acceptability. Additional ingredients such as other bile acid sequestrants, drugs for treating hypercholesterolemia, atherosclerosis or other related indications, or inert ingredients, such as artificial coloring agents can be added as well.
  • suitable forms for administration include tablets, capsules, and powders (e.g., for sprinkling on food) or mixing in water or juice).
  • the tablet, capsule, or powder can be coated with a substance capable of protecting the composition from disintegration in the esophagus but will allow disintegration as the composition in the stomach and mixing with food to pass into the patient's small intestine.
  • the polymer can be administered alone or in combination with a pharmaceutically acceptable carrier substance, e.g., magnesium carbonate, lactose, or a phospholipid with which the polymer can form a micelle.
  • the invention can be used to treat patients, preferably humans, with hypercholesterolemia, particularly patients with a serum LDL level which exceeds about 130 mg/dL.
  • the first step involved the preparation of ethylidenebisacetamide.
  • Acetamide (118 g), acetaldehyde (44.06 g), copper acetate (0.2 g), and water (300 mL) were placed in a 1 L-three neck flask fitted with condenser, thermometer, and mechanical stirred.
  • Concentrated HCl (34 mL) was added and the mixture was heated to 45-50° C. with stirring for 24 hours.
  • the water was then removed in vacuo to leave a thick sludge which formed crystals on cooling to 5° C.
  • Acetone (200 mL) was added and stirred for a few minutes, after which the solid was filtered off and discarded.
  • the acetone was cooled to 0° C. and solid was filtered off. This solid was rinsed in 500 mL acetone and air dried 18 hours to yield 31.5 g of ethylidenebis-acetamide.
  • the next step involved the preparation of vinylacetamide from ethylidenebisacetamide.
  • Ethylidenebisacetamide (31.05 g), calcium carbonate (2 g) and celite 541 (2 g) were-placed in a 500 mL three neck flask fitted with a thermometer, a mechanical stirred, and a distilling heat atop a Vigroux column.
  • the mixture was vacuum distilled at 24 mm Hg by heating the pot to 180-225° C. Only a single fraction was collected (10.8 g) which contained a large portion of acetamide in addition to the product (determined by NMR). This solid product was dissolved in isopropanol (30 mL) to form the crude vinylacetamide solution used for polymerization.
  • Poly(vinylacetamide) (0.79 g) was placed in a 100 mL one neck flask containing water (25 mL) and conc. HCl (25 mL). The mixture was refluxed for 5 days, after which the solid was filtered of L, rinsed once in water, twice in isopropanol, and dried in a vacuum oven to yield 0.77 g of product. Infrared spectroscopy indicated that a significant amount of the amide (1656 cm ⁇ 1 ) remained and that not much amine (1606 cm ⁇ 1 ) was formed. The product of this reaction. ( ⁇ 0.84 g) was suspended in NaOH (46 g) and water (46 g) and heated to boiling ( ⁇ 140° C.).
  • Azobis(amidinopropane) dihydrochloride (0.5 g) suspended in 11 mL of water was then added. The resulting reaction mixture was heated to 50° C. under a nitrogen atmosphere with stirring for 24 hours. Additional azobis(amidinopropane) dihydrochloride. (5 mL) suspended in 11 mL of water was then added, after which heating and stirring were continued for an additional 44 hours.
  • distilled water 100 mL was added to the reaction mixture and the liquid mixture allowed to cool with stirring.
  • the mixture was then removed and placed in a 2 liter separatory funnel, after which it was added dropwise to a stirring solution of methanol (4 L), causing a solid to form.
  • the solid was removed by filtration, re-suspended in methanol (4 L), stirred for 1 hour, and collected by filtration.
  • the methanol rinse was then repeated one more time and the solid dried in a vacuum oven to afford 215.1 g of poly(allylamine) hydrochloride as a granular white solid.
  • poly(allylamine) hydrochloride prepared as described in Example 2 (1 kg) and water (4 L). The mixture was stirred to dissolve the hydrochloride and the pH was adjusted by adding solid NaOH (284 g). The resulting solution was cooled to room temperature, after which epichlorohydrin crosslinking agent (50 mL) was added all at once with stirring. The resulting mixture was stirred gently until it gelled (about 35 minutes). The crosslinking reaction was allowed to proceed for an additional 18 hours at room temperature, after which the polymer gel was removed and placed in portions in a blender with a total of 10 L of water. Each portion was blended gently for about 3 minutes to form coarse particles which were then stirred for 1 hour and collected by filtration.
  • the solid was rinsed three times by suspending it in water (10 L, 15 L, 20 L), stirring each suspension for 1 hour, and collecting the solid each time by filtration.
  • the resulting solid was then rinsed once by suspending it in isopropanol (17 L), stirring the mixture for 1 hour, and then collecting the solid by filtration, after which the solid was dried in a vacuum oven at 50° C. for 18 hours to yield about 677 g of the cross linked polymer as a granular, brittle, white solid.
  • poly(allylamine) hydrochloride prepared as described in Example 2 (500 g) and water (2 L). The mixture was stirred to dissolve the hydrochloride and the pH was adjusted to 10 by adding solid NaOH (134.6 g). The resulting solution was cooled to room temperature in the vessel, after which 1,4-butanedioldiglycidyl ether crosslinking agent (65 mL) was added all at once with stirring. The resulting mixture was stirred gently until it gelled (about 6 minutes). The crosslinking reaction was allowed to proceed for an additional 18 hours at room temperature, after which the polymer gel was removed and dried in a vacuum oven at 75° C. for 24 hours.
  • the dry solid was then ground and sieved to ⁇ 30 mesh, after which it was suspended in 6 gallons of water and stirred for 1 hour. The solid was then filtered off and the rinse process repeated two more times. The resulting solid was then air dried for 4-8 hours, followed by drying in a vacuum oven at 50° C. for 24 hours to yield about 415 g of the crosslinked polymer as a white solid.
  • poly(allylamine) hydrochloride prepared as described in Example 2 (10 g) and water (40 mL). The mixture was stirred to dissolve the hydrochloride and the pH was adjusted to 10 by adding solid NaOH. The resulting solution was cooled to room temperature in the beaker, after which 1,2-ethanedioldiglycidyl ether crosslinking agent (2.0 mL) was added all at once with stirring. The resulting mixture was stirred gently until it gelled (about 4 minutes). The crosslinking reaction was allowed to proceed for an additional 18 hours at room temperature, after which the polymer gel was removed and blended in 500 mL of methanol. The solid was then filtered off and suspended in water (500 mL).
  • poly(allylamine) hydrochloride prepared as described in Example 2 (10 g), methanol (100 mL), and triethylamine (10 mL).
  • the mixture was stirred and dimethylsuccinate crosslinking agent (1 mL) was added.
  • the solution was heated to reflux and the stirring discontinued after 30 minutes. After 18 hours, the solution was cooled to room temperature, and the solid filtered off and blended in 400 mL of isopropanol.
  • the solid was then filtered off and suspended in water (1 L). After stirring for 1 hour, the solid was filtered off and the rinse process repeated two more times.
  • the solid was then rinsed once in isopropanol (800 mL) and dried in a vacuum oven at 50° C. for 24 hours to yield 5.9 g of the crosslinked polymer as a white solid.
  • aqueous solution of poly(allylamine hydrochloride) (550 lb of a 50.7% aqueous solution) was diluted with water (751 lb) and neutralized with aqueous sodium hydroxide (171 lb of a 50% aqueous solution).
  • the solution was cooled to approximately 25° C. and acetonitrile (1340 lb) and epichlorohydrin (26.2 lb) were added.
  • the solution was stirred vigorously for 21 hours. During this time, the reactor contents changed from two liquid phases to a slurry, of particles in a liquid.
  • the solid gel product was isolated by filtration. The gel was washed in an elutriation process with water (136,708 lb).
  • the gel was isolated by filtration and rinsed with isopropanol.
  • the gel was slurried with isopropanol (1269 lb) and isolated by filtration.
  • the isopropanol/water wet gel was dried in a vacuum dryer at 60° C.
  • the dried product was ground to pass through a 50 mesh screen to give a product suitable for pharmacologic use (166 lb, 73w).
  • RenaGel® binder epichlorohydrin cross-linked polyallylamine, GelTex Pharmaceuticals, Inc., Waltham, Mass.
  • Starting doses were either two, three, or four 465 mg capsules three times per day with meals.
  • the dose of RenaGel® binder was increased by one capsule per meal as necessary to achieve a serum phosphorus between 2.5 and 5.5 mg/dL, inclusive. If the serum phosphorus fell to less than 2.5 mg/dL, the RenaGel® binder dose was decreased by one to three capsules per day to elevate the serum phosphorus to above 2.5 mg/dL.
  • the serum calcium level was returned to within the normal range by adding an evening calcium supplement of up to 1,000 mg of elemental calcium as the carbonate salt on an empty stomach at bedtime or the dialysate calcium concentration was increased.
  • TUMS EX® 750 mg tablets containing 300 mg of elemental calcium were provided.
  • Other brands of calcium carbonate or calcium acetate were used if the patient prefered another formulation.
  • the polymer was supplied as capsules containing 500 mg of polymer. Each patient started on one of three doses of polymer: (i) 2 capsules (0.93 g) three times per day with meals; (ii) 3 capsules (1.4 g) three times per day with meals; and (iii) 4 capsules (1.86 g) three times per day with meals.
  • RenaGel® binder epichlorohydrin cross-linked polyallylamine
  • the Figure presents the effect of the the polymer on LDL cholesterol relative to baseline LDL cholesterol.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Abstract

A method for removing bile salts from a patient that includes administering to the patient a therapeutically effective amount of a non-absorbable amine polymers characterized by a repeat unit having the formula:
Figure US20060239959A1-20061026-C00001
 and salts thereof, where n is a positive integer and x is zero or an integer between 1 and about 4.

Description

    RELATED APPLICATIONS
  • This application is a Continuation of U.S. application Ser. No. 10/158,207, filed May 29, 2002, which is a Continuation of U.S. application Ser. No. 08/979,096, filed Nov. 26, 1997, now U.S. Pat. No. 6,423,754 which is a Continuation-in-Part of U.S. application Ser. No.: 08/927,247, filed Sep. 11, 1997 now abandoned, which is a Continuation of U.S. application Ser. No.: 08/878,422, filed Jun. 18, 1997 now abandoned. The entire teachings of the above applications are incorporated herein by reference.
    • BACKGROUND OF THE INVENTION
  • Reabsorption of bile acids from the intestine conserves lipoprotein cholesterol in the bloodstream. Conversely, blood cholesterol levels can be diminished by reducing reabsorption of bile acids.
  • One method of reducing the amount of bile acids that are reabsorbed and, thus, reducing serum cholesterol is the oral administration of compounds that sequester the bile acids and cannot themselves be absorbed. The sequestered bile acids consequently are excreted.
  • Compounds which have been suggested for bile acid sequestration include various ion exchange polymers. One such polymer is cholestyramine, a copolymer of divinylbenzene/styrene and trimethylammonium methylstyrene. It has been long recognized that this polymer is unpalatable, gritty, and constipating. More recently, various polymers have been suggested which are characterized by hydrophobic substituents and quaternary ammonium radicals substituted upon an amine polymer backbone (Ahlers, et al. U.S. Pat. Nos. 5,428,112 and 5,430,110 and McTaggert, et al., U.S. Pat. No. 5,462,730, which are incorporated herein by reference).
  • Thus, there is still a need to discover superior bile acid sequestrants.
    • SUMMARY OF THE INVENTION
  • The invention relates to the unexpected discovery that a new class of ion exchange resins have improved bile salt sequestration properties resulting in reduced dosages, which improve patient tolerance and compliance, thereby improving the palatability of the composition and are relatively easy to manufacture. The polymers, employed in the invention comprise non-absorbable, and optionally cross-linked polyamines as defined herein. The properties of the polymer which gave rise to the present invention were discovered during clinical trials of the polymer for its use in binding phosphate in patients suffering from hyperphosphatemia. The polyamines of the invention are characterized by one or more monomeric units of the formula:
    Figure US20060239959A1-20061026-C00002
    and salts thereof, where n is a positive integer and x is 0 or an integer between 1 and about 4. The polymer can be characterized by the substantial absence of one or more alkylated amine monomers and/or the substantial absence of one or-more trialkylammonium alkyl groups. In preferred embodiments, the polymer is crosslinked by means of a multifunctional crosslinking agent.
  • The invention provides an effective treatment for removing bile salts from a patient (and thereby reducing the patient's cholesterol level), particularly in patients with a serum LDL level of at least about 130 mg/dL. The invention also provides for the use of the polymers described herein for the manufacture of a medicament for the treatment of hypercholesterolemia or for bile acid sequestration.
  • Other features and advantages will be apparent from the following description of the preferred embodiments thereof and from the claims.
    • BRIEF DESCRIPTION OF THE DRAWING.
  • The Figure presents the effect of cross-linked polyallylamine on LDL cholesterol relative to baseline LDL cholesterol.
    • DETAILED DESCRIPTION OF THE INVENTION
  • As described above, the polymers employed in the invention comprise, optionally cross-linked polyamines characterized by the formula above. Preferred polymers are polyallylamine or polyvinylamine. Importantly, the polymers can be characterized by the substantial absence of substituted or unsubstituted alkyl substituents on the amino group of the monomer, such as obtained in the alkylation of an amine polymer. That is, the polymer can be characterized in that the polymer is substantially free of alkylated amine monomers.
  • The polymer can be a homopolymer or a copolymer of one or more amine-containing monomers or non-amine containing monomers. Where copolymers are manufactured with the monomer of the above formula, the comonomers are preferably inert, non-toxic and/or possess bile acid sequestration properties. Examples-of suitable non-amine-containing monomers include vinylalcohol, acrylic acid, acrylamide, and vinylformamide. Examples of amine containing monomers preferably include monomers having the Formula 1 above.
  • Preferably, the monomers are aliphatic. Most preferably, the polymer is a homopolymer, such as a homopolyallylamine or homopolyvinylamine.
  • Preferably, the polymer is rendered water-insoluble by crosslinking. The cross-linking agent can be characterized by functional groups which react with the amino group of the monomer. Alternatively, the crosslinking group can be characterized by two ore more vinyl groups which undergo free radical-polymerization with the amine monomer.
  • Examples of suitable crosslinking agents include acryloyl chloride, epichlorohydrin, butanedioldiglycidyl ether, ethanedioldiglycidyl ether, and dimethyl succinate.
  • A preferred crosslinking agent is epichlorohydrin because of its high availability and low cost. Epichlorohydrin is also advantageous because of it's low molecular weight and hydrophilic nature, maintaining the water-swellability of the polyamine gel.
  • The level of crosslinking makes the polymers insoluble and substantially resistant to absorption and degradation, thereby limiting the activity of the polymer to the gastrointestinal tract. Thus, the compositions are non-systemic in their activity and will lead to reduced side-effects in the patient. Typically, the cross-linking agent is present in an amount from about 0.5-25% (more preferably about 2.5-20% and most preferably 1-10%). by weight, based upon total weight of monomer plus crosslinking agent.
  • Typically, the amount of crosslinking-agent that is reacted with the amine polymer is sufficient to cause between about 0.5 and twenty percent of the amines. In a preferred embodiment, between about 0.5 and 20 percent of the amine groups react with the crosslinking agent.
  • Preferred polymers of the invention are generally known in the art. Holmes-Farley, et al. (U.S. Pat. No. 5,496,545), describes the use of aliphatic amine polymers in the treatment of hyperphosphatemia. These polymers have also been suggested for use in the treatment of iron-overload (Mandeville, et al., U.S. Pat. No. 5,487,888). The teachings of both of these patents are incorporated herein by reference.
  • Non-cross-linked and cross-linked polyallylamine and polyvinylamine are generally known in the art and/or are commercially available. Methods for the manufacture of polyallylamine and polyvinylamine, and cross-linked derivatives thereof, are described in the above US Patents, the teachings of which are incorporated entirely by reference. Harada et al. (U.S. Pat. Nos. 4,605,701 and 4,528,347, which are incorporated herein by reference in their entirety) also describe methods of manufacturing polyallylamine and cross-linked polyallylamine.
  • As described above the polymer can be administered in the form of a salt. By “salt” it is meant that the nitrogen group in the repeat unit is protonated to create a positively charged nitrogen atom associated with a negatively charged counterion.
  • The cationic counterions can be selected to minimize adverse effects on the patient, as is more particularly described below. Examples of suitable counterions include Cl−, Br−, CH3OSO3 −, HSO4 −, SO4 2−, HCO3 −, CO3 −, acetate, lactate, succinate, propionate, butyrate, ascorbate, citrate, maleate, folate, an amino acid derivative, a nucleotide, a lipid, or a phospholipid. The counterions can be the same as, or different from, each other. For example, the reaction product can contain two different types of counterions, both of which are exchanged for the bile salts being removed.
  • The polymers according to the invention can be administered orally to a patient in a dosage of about 1 mg/kg/day to about 1 g/kg/day, preferably between about 5 mg/kg/day to about 200 mg/kg/day (such as between about 10 mg/kg/day to about 200 mg/kg/day); the particular dosage will depend on the individual-patient (e.g., the patient's weight and the extent of bile salt removal required). The polymer can be administrated either in hydrated or dehydrated form, and can be flavored or added to a food or drink, if desired to enhance patient acceptability. Additional ingredients such as other bile acid sequestrants, drugs for treating hypercholesterolemia, atherosclerosis or other related indications, or inert ingredients, such as artificial coloring agents can be added as well.
  • Examples of suitable forms for administration include tablets, capsules, and powders (e.g., for sprinkling on food) or mixing in water or juice). The tablet, capsule, or powder can be coated with a substance capable of protecting the composition from disintegration in the esophagus but will allow disintegration as the composition in the stomach and mixing with food to pass into the patient's small intestine. The polymer can be administered alone or in combination with a pharmaceutically acceptable carrier substance, e.g., magnesium carbonate, lactose, or a phospholipid with which the polymer can form a micelle.
  • The invention can be used to treat patients, preferably humans, with hypercholesterolemia, particularly patients with a serum LDL level which exceeds about 130 mg/dL.
  • The invention will now be described more specifically by the examples.
    • EXAMPLES
  • A. Polymer Preparation
  • 1. Preparation of Poly(vinylamine)
  • The first step involved the preparation of ethylidenebisacetamide. Acetamide (118 g), acetaldehyde (44.06 g), copper acetate (0.2 g), and water (300 mL) were placed in a 1 L-three neck flask fitted with condenser, thermometer, and mechanical stirred. Concentrated HCl (34 mL) was added and the mixture was heated to 45-50° C. with stirring for 24 hours. The water was then removed in vacuo to leave a thick sludge which formed crystals on cooling to 5° C. Acetone (200 mL) was added and stirred for a few minutes, after which the solid was filtered off and discarded. The acetone was cooled to 0° C. and solid was filtered off. This solid was rinsed in 500 mL acetone and air dried 18 hours to yield 31.5 g of ethylidenebis-acetamide.
  • The next step involved the preparation of vinylacetamide from ethylidenebisacetamide. Ethylidenebisacetamide (31.05 g), calcium carbonate (2 g) and celite 541 (2 g) were-placed in a 500 mL three neck flask fitted with a thermometer, a mechanical stirred, and a distilling heat atop a Vigroux column. The mixture was vacuum distilled at 24 mm Hg by heating the pot to 180-225° C. Only a single fraction was collected (10.8 g) which contained a large portion of acetamide in addition to the product (determined by NMR). This solid product was dissolved in isopropanol (30 mL) to form the crude vinylacetamide solution used for polymerization.
  • Crude vinylacetamide solution (15 mL), divinylbenzene (1 g, technical grade, 55% pure, mixed isomers), and AIBN (0.3 g) were mixed and heated to reflux under a nitrogen atmosphere for 90 minutes, forming a solid precipitate. The solution was cooled, isopropanol. (50 mL) was added, and the solid was collected by centrifugation. The solid was rinsed twice in isopropanol, once in water, and dried in a vacuum oven to yield 0.8 g of poly(vinylacetamide), which was used to prepare poly(vinylamine).
  • Poly(vinylacetamide) (0.79 g) was placed in a 100 mL one neck flask containing water (25 mL) and conc. HCl (25 mL). The mixture was refluxed for 5 days, after which the solid was filtered of L, rinsed once in water, twice in isopropanol, and dried in a vacuum oven to yield 0.77 g of product. Infrared spectroscopy indicated that a significant amount of the amide (1656 cm−1) remained and that not much amine (1606 cm−1) was formed. The product of this reaction. (˜0.84 g) was suspended in NaOH (46 g) and water (46 g) and heated to boiling (˜140° C.). Due to foaming the temperature was reduced and maintained at ˜100° C. for 2 hours. Water (10.0 mL) was added and the solid collected by filtration. After rinsing once in water the solid was suspended in water (500 mL) and adjusted to pH 5 with acetic acid. The solid was again filtered off, rinsed with water, then isopropanol, and dried in a vacuum oven to yield 0.51 g of product. Infrared spectroscopy indicated that significant amine-had been formed.
  • 2. Preparation of Poly(allylamine) Hydrochloride
  • To a 2 liter, water-jacketed reaction kettle equipped with (1) a condenser topped with a nitrogen gas inlet, (2) a thermometer, and (3) a mechanical stirrer was added concentrated hydrochloric acid (360 mL). The acid was cooled to 5° C. using circulating water in the jacket of the reaction kettle (water temperature=0° C.). Allylamine (328.5 mL, 250 g) was added dropwise with stirring while maintaining the reaction temperature at 5-10° C. After addition was complete, the mixture was removed, placed in a 3 liter one-neck flask, and 206 g of liquid was removed by rotary vacuum evaporation at 60° C. Water (20 mL) was then added and the liquid was returned to the reaction kettle. Azobis(amidinopropane) dihydrochloride (0.5 g) suspended in 11 mL of water was then added. The resulting reaction mixture was heated to 50° C. under a nitrogen atmosphere with stirring for 24 hours. Additional azobis(amidinopropane) dihydrochloride. (5 mL) suspended in 11 mL of water was then added, after which heating and stirring were continued for an additional 44 hours.
  • At the end of this period, distilled water (100 mL) was added to the reaction mixture and the liquid mixture allowed to cool with stirring. The mixture was then removed and placed in a 2 liter separatory funnel, after which it was added dropwise to a stirring solution of methanol (4 L), causing a solid to form. The solid was removed by filtration, re-suspended in methanol (4 L), stirred for 1 hour, and collected by filtration. The methanol rinse was then repeated one more time and the solid dried in a vacuum oven to afford 215.1 g of poly(allylamine) hydrochloride as a granular white solid.
  • 3. Preparation of Poly(allylamine) Hydrochloride Crosslinked with Epichlorohydrin
  • To a 5 gallon vessel was added poly(allylamine) hydrochloride prepared as described in Example 2 (1 kg) and water (4 L). The mixture was stirred to dissolve the hydrochloride and the pH was adjusted by adding solid NaOH (284 g). The resulting solution was cooled to room temperature, after which epichlorohydrin crosslinking agent (50 mL) was added all at once with stirring. The resulting mixture was stirred gently until it gelled (about 35 minutes). The crosslinking reaction was allowed to proceed for an additional 18 hours at room temperature, after which the polymer gel was removed and placed in portions in a blender with a total of 10 L of water. Each portion was blended gently for about 3 minutes to form coarse particles which were then stirred for 1 hour and collected by filtration. The solid was rinsed three times by suspending it in water (10 L, 15 L, 20 L), stirring each suspension for 1 hour, and collecting the solid each time by filtration. The resulting solid was then rinsed once by suspending it in isopropanol (17 L), stirring the mixture for 1 hour, and then collecting the solid by filtration, after which the solid was dried in a vacuum oven at 50° C. for 18 hours to yield about 677 g of the cross linked polymer as a granular, brittle, white solid.
  • 4. Preparation of Poly(allylamine) Hydrochloride Crosslinked with Butanedioldiglycidyl Ether
  • To a 5 gallon vessle was added poly(allylamine) hydrochloride prepared as described in Example 2 (500 g) and water (2 L). The mixture was stirred to dissolve the hydrochloride and the pH was adjusted to 10 by adding solid NaOH (134.6 g). The resulting solution was cooled to room temperature in the vessel, after which 1,4-butanedioldiglycidyl ether crosslinking agent (65 mL) was added all at once with stirring. The resulting mixture was stirred gently until it gelled (about 6 minutes). The crosslinking reaction was allowed to proceed for an additional 18 hours at room temperature, after which the polymer gel was removed and dried in a vacuum oven at 75° C. for 24 hours. The dry solid was then ground and sieved to −30 mesh, after which it was suspended in 6 gallons of water and stirred for 1 hour. The solid was then filtered off and the rinse process repeated two more times. The resulting solid was then air dried for 4-8 hours, followed by drying in a vacuum oven at 50° C. for 24 hours to yield about 415 g of the crosslinked polymer as a white solid.
  • 5. Preparation of Poly(allylamine) Hydrochloride Crosslinked with Ethanedioldiglycidyl Ether
  • To a 100 mL beaker was added poly(allylamine) hydrochloride prepared as described in Example 2 (10 g) and water (40 mL). The mixture was stirred to dissolve the hydrochloride and the pH was adjusted to 10 by adding solid NaOH. The resulting solution was cooled to room temperature in the beaker, after which 1,2-ethanedioldiglycidyl ether crosslinking agent (2.0 mL) was added all at once with stirring. The resulting mixture was stirred gently until it gelled (about 4 minutes). The crosslinking reaction was allowed to proceed for an additional 18 hours at room temperature, after which the polymer gel was removed and blended in 500 mL of methanol. The solid was then filtered off and suspended in water (500 mL). After stirring for 1 hour, the solid was filtered off and the rinse process repeated. The resulting solid was rinsed twice in isopropanol (400 mL) and then dried-in a vacuum oven at 50° C. for 24 hours to yield 8.7 g of the crosslinked polymer as a white solid.
  • 6. Preparation of Poly(allylamine) Hydrochloride Crosslinked with Dimethylsuccinate
  • To a 500 mL round-bottomed flask was added poly(allylamine) hydrochloride prepared as described in Example 2 (10 g), methanol (100 mL), and triethylamine (10 mL). The mixture was stirred and dimethylsuccinate crosslinking agent (1 mL) was added. The solution was heated to reflux and the stirring discontinued after 30 minutes. After 18 hours, the solution was cooled to room temperature, and the solid filtered off and blended in 400 mL of isopropanol. The solid was then filtered off and suspended in water (1 L). After stirring for 1 hour, the solid was filtered off and the rinse process repeated two more times. The solid was then rinsed once in isopropanol (800 mL) and dried in a vacuum oven at 50° C. for 24 hours to yield 5.9 g of the crosslinked polymer as a white solid.
  • An aqueous solution of poly(allylamine hydrochloride) (550 lb of a 50.7% aqueous solution) was diluted with water (751 lb) and neutralized with aqueous sodium hydroxide (171 lb of a 50% aqueous solution). The solution was cooled to approximately 25° C. and acetonitrile (1340 lb) and epichlorohydrin (26.2 lb) were added. The solution was stirred vigorously for 21 hours. During this time, the reactor contents changed from two liquid phases to a slurry, of particles in a liquid. The solid gel product was isolated by filtration. The gel was washed in an elutriation process with water (136,708 lb). The gel was isolated by filtration and rinsed with isopropanol. The gel was slurried with isopropanol (1269 lb) and isolated by filtration. The isopropanol/water wet gel was dried in a vacuum dryer at 60° C. The dried product was ground to pass through a 50 mesh screen to give a product suitable for pharmacologic use (166 lb, 73w).
  • 7. Effect on Serum Cholesterol Levels in Humans
  • Hemodialysis patients on stable doses of calcium and/or aluminum based phosphate binders entered a one-week screening period. The phosphate binders were discontinued.
  • Those patients developing hyperphosphatemia (serum P04>6.0 mg/dL) during the wash-out period were eligible for drug treatment. A RenaGel® binder (epichlorohydrin cross-linked polyallylamine, GelTex Pharmaceuticals, Inc., Waltham, Mass.) starting dose was based on the degree of hyperphosphatemia. Starting doses were either two, three, or four 465 mg capsules three times per day with meals. At the end of each of three subsequent two week periods, the dose of RenaGel® binder was increased by one capsule per meal as necessary to achieve a serum phosphorus between 2.5 and 5.5 mg/dL, inclusive. If the serum phosphorus fell to less than 2.5 mg/dL, the RenaGel® binder dose was decreased by one to three capsules per day to elevate the serum phosphorus to above 2.5 mg/dL.
  • When the serum calcium fell below normal (defined by the central laboratory normal range) during the study, the serum calcium level was returned to within the normal range by adding an evening calcium supplement of up to 1,000 mg of elemental calcium as the carbonate salt on an empty stomach at bedtime or the dialysate calcium concentration was increased. TUMS EX® 750 mg tablets containing 300 mg of elemental calcium were provided. Other brands of calcium carbonate or calcium acetate were used if the patient prefered another formulation.
  • At the conclusion of the treatment period, any remaining RenaGel® capsules were retrieved and the patient was kept off phosphate binder for two weeks. After this second wash-out period, patients discontinued any evening calcium supplements and returned to their original phosphate binders.
  • Weekly throughout this period, on Mondays (MWF patients) and Tuesdays (TTS patients), the patients gave blood for the laboratory studies just prior to dialysis. On the Wednesdays (MWF patients) and Thursdays (TTS patients) of the same weeks, the investigator inquired if the patient experienced any adverse events or had changes in medications that might indicate adverse events and reviewed the results of the laboratory tests.
  • Dietary intakes of phosphorus were assessed on selected days in the first wash-out, treatment, and second wash-out periods by 24-hour recall methods by nutritionists from the University of Massachusetts Medical Center
  • Approximately 216 hemodialysis patients on stable doses of phosphate binders were entered into the study. The patients had to have well controlled serum phosphorus and not have any clinically significant unstable medical conditions. Only those patients who were hyperphosphatemiic (serum P04<6.0 mg/dL) during the first washout period (approximately 180 patients) received treatment.
  • The polymer was supplied as capsules containing 500 mg of polymer. Each patient started on one of three doses of polymer: (i) 2 capsules (0.93 g) three times per day with meals; (ii) 3 capsules (1.4 g) three times per day with meals; and (iii) 4 capsules (1.86 g) three times per day with meals.
    Dose Level***
    Overall Low Medium High
    Std P- Std Std Std P-
    Parameter Visit N Mean Dev Value* N Mean Dev N Mean Dev N Mean Dev Value**
    Total Cholesterol −1 28 214.6 41.2 13 217.0 42.4 3 267.3 57.4 12 198.8 23.8 0.0978
    (mg/dL)
    2 29 221.7 35.6 13 216.5 35.0 4 261.8 46.1 12 214.0 25.1 0.0790
    6 28 182.2 46.2 12 186.8 44.1 4 234.8 63.1 12 160.1 25.6 0.0222
    10 25 184.7 48.5 12 195.5 47.7 4 223.5 52.9 9 153.1 29.0 0.0181
    10/Final 25 184.7 48.5 12 195.5 47.7 4 223.5 52.9 9 153.1 29.0 0.0181
    Change(10/Final − 2) 25 −37.2 29.0 <0.0001 12 −22.3 27.3 4 −38.3 25.3 9 −56.7 22.3 0.0098
    12 25 208.1 42.1 12 202.6 38.4 4 267.3 45.6 9 189.2 18.0 0.0291
    Change(12 − 10) 24 23.1 34.2 0.0006 12 7.1 40.7 4 43.8 12.9 8 36.8 16.2 0.0306
    LDL Cholesterol −1 27 145.0 34.1 12 147.2 32.2 3 191.1 40.2 12 131.2 24.9 0.0494
    (mg/dL)
    2 29 154.6 27.4 13 147.4 16.3 4 184.6 46.2 12 152.3 25.3 0.1441
    6 28 110.5 33.4 12 113.3 32.4 4 150.5 43.9 12 94.5 17.3 0.0085
    10 25 109.0 37.7 12 109.5 34.6 4 141.0 45.6 9 94.2 32.7 0.1750
    10/Final 25 109.0 37.7 12 109.5 34.6 4 141.0 45.6 9 94.2 32.7 0.1750
    Change(10/Final − 2) 25 −45.7 29.3 <0.0001 12 −38.0 29.0 4 −43.6 28.0 9 −56.8 29.9 0.2972
    12 25 141.0 33.6 12 132.3 20.9 4 194.2 37.9 9 129.0 23.8 0.0221
    Change(12 − 10) 24 33.0 24.8 <0.0001 12 22.8 23.6 4 53.2 17.9 8 38.2 23.9 0.0503
    HDL Cholesterol −1 27 37.6 9.4 12 39.6 10.1 3 32.7 4.7 12 36.8 9.6 0.5108
    (mg/dL)
    2 29 36.4 9.2 13 37.8 9.8 4 31.3 5.0 12 36.5 9.6 0.4077
    6 28 38.5 10.5 12 40.3 13.1 4 37.0 7.4 12 37.3 8.6 0.6622
    10 25 36.5 11.1 12 41.3 12.0 4 34.5 6.1 9 30.9 9.3 0.1053
    10/Final 25 36.5 11.1 12 41.3 12.0 4 34.5 6.1 9 30.9 9.3 0.1053
    Change(10/Final − 2) 25 0.8 9.0 0.2823 12 2.8 10.3 4 3.3 3.0 9 −3.0 8.2 0.1000
    12 25 38.6 11.3 12 42.0 10.1 4 35.5 5.3 9 35.6 14.2 0.1986
    Change(12 − 10) 24 0.9 8.5 0.8018 12 0.7 7.7 4 1.0 2.7 8 1.3 11.8 0.7914
    Triglycerides −1 28 165.8 80.5 13 164.7 93.9 3 217.7 113.0 12 153.9 55.3 0.5796
    (mg/dL)
    2 29 153.9 92.3 13 156.3 103.7 4 229.5 104.0 12 126.2 64.0 0.2165
    6 28 165.5 89.5 12 165.7 80.8 4 236.5 123.4 12 141.7 80.7 0.2408
    10 25 196.2 165.3 12 223.4 222.6 4 240.0 65.1 9 140.3 81.8 0.0994
    10/Final 25 196.2 165.3 12 223.4 222.6 4 240.0 65.1 9 140.3 81.8 0.0994
    Change(10/Final − 2) 25 38.2 150.6 0.3161 12 64.3 214.4 4 10.5 55.2 9 15.8 41.0 0.9199
    12 25 142.5 91.2 12 141.7 107.2 4 188.0 76.3 9 123.4 74.3 0.2964
    Change(12 − 10) 24 −54.0 151.3 0.0135 12 −81.8 209.6 4 −52.0 34.7 8 −13.4 49.7 0.2320

    *Wilcoxon Signed Rank Test

    **Kruskal-Wallis Exact Test

    ***Dose level defined using the last actual dose during study

    8. Effect in Healthy Young and Old, Male and Female Volunteers
  • Eight young (19-40 years of age) and eight old (65 years of age and older) healthy volunteer male and female subjects received 2.325 grams of RenaGel® binder (epichlorohydrin cross-linked polyallylamine) three times per day with meals for 32 days. All drug doses were administered with meals served at a clinical research center for the entire 32 day study. On day 0, a 10 mL blood sample was drawn prior to the morning meal and analyzed for plasma cholesterol levels. On day 32 a second 10 mL blood sample was drawn prior to the morning meal. Subjects were released from the study after the morning meal on day 32. Plasma triglycerides and HDL were measured and LDL cholesterol was calculated by the Friedewald formula.
  • The Figure presents the effect of the the polymer on LDL cholesterol relative to baseline LDL cholesterol. The higher the baseline cholesterol in these normal volunteers, the greater the decline in LDL cholesterol. LDL cholesterol declined by a mean of 42 mg/dL for the entire 16 patient cohort. Five patients in the study had baseline LDL cholesterol lower than 100 mg/dL. The decline in LDL cholesterol in the 11 patients with baseline LDL cholesterol>than 120 mg/dL was 52.5 mg/dL.
    • EQUIVALENTS
  • Those skilled in the art will know, or be able to ascertain, using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. These and all other equivalents are intended to be encompassed by the following claims.

Claims (6)

1-15. (canceled)
16. A method of removing bile salts from a patient comprising administering to said patient a therapeutically effective amount of cross-linked homopolyallylamine,
wherein
said cross-linked homopolyallylamine is cross-linked by a multifunctional crosslinking agent, and
said multifunctional crosslinking agent is present in an amount from 0.5-25% by weight, based upon the combined weight of allylamine repeat units and multifunctional crosslinking agent.
17. The method of claim 16 wherein said multifunctional crosslinking agent is present in an amount from about 2.5-20% by weight, based upon the combined weight of allylamine repeat units and multifunctional crosslinking agent.
18. The method of claim 16, wherein the patient has a serum LDL level of at least 130 mg/dL.
19. The method of claim 16, wherein the multifunctional crosslinking agent comprises epichlorohydrin.
20. The method of claim 16, wherein the multifunctional crosslinking Agent is epichlorohydrin.
US11/344,862 1997-06-18 2006-02-01 Method for treating hypercholesterolemia with polyallylamine polymers Abandoned US20060239959A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/344,862 US20060239959A1 (en) 1997-06-18 2006-02-01 Method for treating hypercholesterolemia with polyallylamine polymers

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US87842297A 1997-06-18 1997-06-18
US92724797A 1997-09-11 1997-09-11
US08/979,096 US6423754B1 (en) 1997-06-18 1997-11-26 Method for treating hypercholesterolemia with polyallylamine polymers
US10/158,207 US20030086898A1 (en) 1997-06-18 2002-05-29 Method for treating hypercholesterolemia with polyallylamine polymers
US11/344,862 US20060239959A1 (en) 1997-06-18 2006-02-01 Method for treating hypercholesterolemia with polyallylamine polymers

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/158,207 Continuation US20030086898A1 (en) 1997-06-18 2002-05-29 Method for treating hypercholesterolemia with polyallylamine polymers

Publications (1)

Publication Number Publication Date
US20060239959A1 true US20060239959A1 (en) 2006-10-26

Family

ID=27420493

Family Applications (3)

Application Number Title Priority Date Filing Date
US08/979,096 Expired - Lifetime US6423754B1 (en) 1997-06-18 1997-11-26 Method for treating hypercholesterolemia with polyallylamine polymers
US10/158,207 Abandoned US20030086898A1 (en) 1997-06-18 2002-05-29 Method for treating hypercholesterolemia with polyallylamine polymers
US11/344,862 Abandoned US20060239959A1 (en) 1997-06-18 2006-02-01 Method for treating hypercholesterolemia with polyallylamine polymers

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US08/979,096 Expired - Lifetime US6423754B1 (en) 1997-06-18 1997-11-26 Method for treating hypercholesterolemia with polyallylamine polymers
US10/158,207 Abandoned US20030086898A1 (en) 1997-06-18 2002-05-29 Method for treating hypercholesterolemia with polyallylamine polymers

Country Status (16)

Country Link
US (3) US6423754B1 (en)
EP (1) EP0996454B1 (en)
JP (1) JP4420143B2 (en)
KR (1) KR100567751B1 (en)
CN (1) CN1211091C (en)
AT (1) ATE249228T1 (en)
AU (1) AU735260C (en)
CA (1) CA2294036C (en)
DE (1) DE69818058T2 (en)
HK (1) HK1029920A1 (en)
IL (1) IL133434A (en)
MX (1) MXPA99011826A (en)
MY (1) MY125874A (en)
NZ (1) NZ501719A (en)
TW (1) TW526063B (en)
WO (1) WO1998057652A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009078956A1 (en) * 2007-12-14 2009-06-25 Genzyme Corporation Pharmaceutical compositions
US8163799B2 (en) 2006-12-14 2012-04-24 Genzyme Corporation Amido-amine polymer compositions
US8425887B2 (en) 2006-09-29 2013-04-23 Genzyme Corporation Amide dendrimer compositions
US8808738B2 (en) 2004-11-01 2014-08-19 Genzyme Corporation Aliphatic amine polymer salts for tableting
US8986669B2 (en) 2005-09-02 2015-03-24 Genzyme Corporation Method for removing phosphate and polymer used therefore
US9579343B2 (en) 1999-10-19 2017-02-28 Genzyme Corporation Direct compression polymer tablet core
US9585911B2 (en) 2005-09-15 2017-03-07 Genzyme Corporation Sachet formulation for amine polymers

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW568788B (en) * 1998-10-12 2004-01-01 Chugai Pharmaceutical Co Ltd Polymer combining with phosphoric acid and preparation containing the same
EP1293211A1 (en) * 1998-12-23 2003-03-19 G.D. Searle LLC. Combinations of ileal bile acid transport inhibitors and bile acid sequestering agents for cardiovascular indications
WO2000063259A1 (en) * 1999-04-16 2000-10-26 Abbott Laboratories Process for producing cross-linked polyallylamine hydrochloride
US6362266B1 (en) 1999-09-03 2002-03-26 The Dow Chemical Company Process for reducing cohesiveness of polyallylamine polymer gels during drying
US6180754B1 (en) 1999-09-03 2001-01-30 The Dow Chemical Company Process for producing cross-linked polyallylamine polymer
US20020054903A1 (en) * 1999-10-19 2002-05-09 Joseph Tyler Direct compression polymer tablet core
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
WO2002085379A1 (en) * 2001-04-18 2002-10-31 Geltex Pharmaceuticals, Inc. Method for improving vascular access in patients with vascular shunts
MXPA03009562A (en) * 2001-04-18 2004-02-12 Genzyme Corp Methods of treating syndrome x with aliphatic polyamines.
PT1923064T (en) 2001-04-18 2017-08-23 Genzyme Corp Use of amine polymer for lowering serum glucose
EP1379258B1 (en) * 2001-04-18 2006-06-28 Genzyme Corporation Low salt forms of polyallylamine
JP2005510524A (en) * 2001-11-16 2005-04-21 アルス・セラピー・デベロツプメント・フアンデーシヨン・インコーポレーテツド Treatment of neurodegenerative disorders by modulating the polyamine pathway
AU2003282867A1 (en) * 2002-10-22 2004-05-13 Genzyme Corporation Amine polymers for promoting bone formation
US7608674B2 (en) * 2003-11-03 2009-10-27 Ilypsa, Inc. Pharmaceutical compositions comprising cross-linked small molecule amine polymers
US7449605B2 (en) * 2003-11-03 2008-11-11 Ilypsa, Inc. Crosslinked amine polymers
US7459502B2 (en) 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7385012B2 (en) 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
US7767768B2 (en) * 2003-11-03 2010-08-03 Ilypsa, Inc. Crosslinked amine polymers
US7335795B2 (en) * 2004-03-22 2008-02-26 Ilypsa, Inc. Crosslinked amine polymers
WO2005051298A2 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
PL3219312T3 (en) 2004-03-30 2019-07-31 Relypsa, Inc. Ion binding polymers and uses thereof
US20050244367A1 (en) * 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen
US20050276781A1 (en) * 2004-06-09 2005-12-15 Ross Edward A Molecularly imprinted phosphate binders for therapeutic use
US20060177415A1 (en) * 2004-11-01 2006-08-10 Burke Steven K Once a day formulation for phosphate binders
JP2008533272A (en) * 2005-03-16 2008-08-21 ユーエスヴィー リミテッド Improved method for the preparation of crosslinked polyallylamine polymers
JP2008545711A (en) 2005-05-26 2008-12-18 メタバシス・セラピューティクス・インコーポレイテッド Novel phosphatic acid-containing thyroid hormone-like agent
AR056499A1 (en) * 2005-09-06 2007-10-10 Serapis Farmaceuticals Ltd COMPOUNDS
JP2009536246A (en) * 2006-05-05 2009-10-08 ゲンズイメ コーポレーション Amine condensation polymers as phosphate scavengers.
WO2008011047A2 (en) * 2006-07-18 2008-01-24 Genzyme Corporation Amine dendrimers
EP2076286B1 (en) * 2006-10-25 2016-03-09 Wisconsin Alumni Research Foundation Methods of reducing phosphate absorption using an anti-npt2b antibody
US8877198B2 (en) * 2006-10-26 2014-11-04 Wisconsin Alumni Research Foundation Methods of reducing phosphate absorption
HUE046465T2 (en) 2006-12-22 2020-03-30 Ironwood Pharmaceuticals Inc Compositions comprising bile acid sequestrants for treating esophageal disorders
WO2008103368A1 (en) * 2007-02-23 2008-08-28 Genzyme Corporation Amine polymer compositions
EP2131820A1 (en) * 2007-03-08 2009-12-16 Genzyme Corporation Sulfone polymer compositions
EP2152277A1 (en) * 2007-04-27 2010-02-17 Genzyme Corporation Amido-amine dendrimer compositions
US20100316589A1 (en) * 2007-12-14 2010-12-16 Hitesh Bhagat Coated Pharmaceutical Compositions
WO2009154747A1 (en) * 2008-06-20 2009-12-23 Genzyme Corporation Pharmaceutical compositions
US8404784B2 (en) * 2008-12-03 2013-03-26 Navinta Llc Manufacturing process of making polymeric amine salts
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
IT1394299B1 (en) * 2009-05-12 2012-06-06 Chimico Internaz Spa Lab PROCEDURE FOR THE PREPARATION OF SEVELAMER
JP5285000B2 (en) * 2010-02-23 2013-09-11 富士フイルム株式会社 Method for measuring low density lipoprotein cholesterol
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9486433B2 (en) 2012-10-12 2016-11-08 Mochida Pharmaceuticals Co. Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
JP6442412B2 (en) 2013-03-15 2018-12-19 持田製薬株式会社 Compositions and methods for the treatment of non-alcoholic steatohepatitis
CN112047854B (en) * 2020-10-20 2021-07-02 中国科学院长春应用化学研究所 Preparation method of N-vinyl alkyl amide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624963A (en) * 1993-06-02 1997-04-29 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US5792749A (en) * 1997-01-09 1998-08-11 Virginia Commonwealth University Method and composition for lowering low density lipoprotein cholesterol

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB798488A (en) 1956-01-09 1958-07-23 Nat Aluminate Corp Quaternary ammonium compounds and method for the preparation thereof
US2874132A (en) 1956-11-02 1959-02-17 Rohm & Haas Anion-exchange resins for sugar decolorization and their preparation
BE580490A (en) 1958-07-15 1960-01-08 Merck & Co Inc Compositions and methods for lowering the cholesterol content of the blood
US3383281A (en) 1961-09-22 1968-05-14 Merck & Co Inc Method for binding bile acids in vivo
US3308020A (en) 1961-09-22 1967-03-07 Merck & Co Inc Compositions and method for binding bile acids in vivo including hypocholesteremics
US3288770A (en) 1962-12-14 1966-11-29 Peninsular Chem Res Inc Water soluble quaternary ammonium polymers
CH486202A (en) 1966-05-31 1970-02-28 Agripat Sa Microbicidal agent
US3562266A (en) 1969-05-26 1971-02-09 Montedison Spa Quaternary ammonium halides having a 2-chloro cyclohexyl or 2-chloro alkyl substituent
BE756035A (en) 1969-09-12 1971-03-11 Inveresk Res Int POLYMERS BRIDGES
US3803237A (en) 1969-11-03 1974-04-09 Upjohn Co Reaction products of polyethylenepolyamines and chlorohydrins or epoxy containing compounds
NL7017227A (en) 1969-12-27 1971-06-29
US3692895A (en) 1970-09-08 1972-09-19 Norman A Nelson Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria
US3980770A (en) 1971-06-04 1976-09-14 Pharmacia Aktiebolag Polymerization products containing amino groups useful in serum cholesterol level control
US4027009A (en) 1973-06-11 1977-05-31 Merck & Co., Inc. Compositions and methods for depressing blood serum cholesterol
US4205064A (en) 1973-06-11 1980-05-27 Merck & Co., Inc. Bile acid sequestering composition containing poly[{alkyl-(3-ammoniopropyl)imino}-trimethylenedihalides]
US4217429A (en) 1973-06-11 1980-08-12 Merck & Co., Inc. Poly-[(methylimino)trimethylene]
CS187563B1 (en) 1974-02-08 1979-02-28 Petr Strop Method of preparation of the hydrophilic homogeneous or macroporous annexes
CS173201B1 (en) 1974-02-13 1977-02-28
US4016209A (en) 1975-04-23 1977-04-05 Merck & Co., Inc. 3-[N'-(3-Halopropyl)-N-'-methylamino]-N,N,N-trimethyl-1-propanaminium halide and acid addition salts thereof
US4071478A (en) 1976-06-07 1978-01-31 Merck & Co., Inc. Controlled partially cross-linked 3,3-ionenes
FI67483C (en) 1977-02-17 1985-04-10 Merck & Co Inc PROCEDURE FOR THE FRAMEWORK OF ETHCYCLE ADMINISTRATION OF PHARMACOLOGICAL PRODUCT AGAINST GALLSYRAK COMPLEX BILDANDE ADSORBATE PREPARATION
IT1106718B (en) 1978-12-21 1985-11-18 Alfa Farmaceutici Spa PHARMACOLOGICALLY ACTIVE SALONIZED ANIONIC RESIN BASED COMPOSITIONS
US4426489A (en) 1980-02-21 1984-01-17 The Dow Chemical Company Surface active polymeric surfactants containing side chain hydrophobes
GB2090605B (en) 1980-12-12 1984-09-05 Smith & Nephew Ass Polymer of diallyl ammonium monomers pharmaceutical compositions thereof
JPS5879022A (en) 1981-11-04 1983-05-12 Bitamin Kenkyusho:Kk Novel metal-crosslinked polymer compound containing quaternary nitrogen atom, its preparation, and remedy for hyperlipemia containing said polymer compound as active component
WO1983002392A1 (en) 1982-01-18 1983-07-21 Kihara, Kunio Cholesterol lowering drug
JPS6090243A (en) 1983-10-25 1985-05-21 Nitto Boseki Co Ltd Small spherical crosslinked monoallylamine polymer and its preparation
CA1220896A (en) 1983-11-10 1987-04-21 Susumu Harada Process for producing polymers of monoallylamine
AU551886B2 (en) 1983-11-14 1986-05-15 Nitto Boseki Co. Ltd. Poly(allylamine) derivatives
JPS60106803A (en) 1983-11-14 1985-06-12 Nitto Boseki Co Ltd Production of allylurea polymer
US4540760A (en) 1984-01-11 1985-09-10 Nitto Boseki Co. Ltd. Process for producing polymers of monoallylamine
EP0162388B1 (en) 1984-05-11 1989-09-13 Bristol-Myers Company Novel bile sequestrant resin and uses
US4759923A (en) 1987-06-25 1988-07-26 Hercules Incorporated Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives
DE3800199A1 (en) 1988-01-07 1989-07-20 Sandoz Ag VINYL POLYMERS WITH SIDE CHAINS
GB8829088D0 (en) 1988-12-13 1989-01-25 Smith Kline French Lab Compounds
US5236701A (en) 1989-07-19 1993-08-17 Lowchol Scientific Inc. Ingestible hydrophilic polymeric amines useful for lowering blood cholesterol
GB8928278D0 (en) 1989-12-14 1990-02-21 Smith Kline French Lab Compounds
CA2040996A1 (en) 1990-05-02 1991-11-03 Robert L. Albright Composition and method for controlling cholesterol
GB9011332D0 (en) 1990-05-21 1990-07-11 Smith Kline French Lab Compounds
IE914179A1 (en) 1990-12-07 1992-06-17 Ici Plc Nitrogen derivatives
US5055197A (en) 1991-04-05 1991-10-08 Rohm And Haas Company Process for removing residual monomers and oligemers from amine-containing polymers
JP3247435B2 (en) 1992-07-11 2002-01-15 日産アルティア株式会社 Manufacturing method of resin-made vehicle roof rail with core material added and vehicle roof rail
ATE159262T1 (en) 1992-07-22 1997-11-15 Hoechst Ag POLYVINYLAMINE DERIVATIVES HAVING HYDROPHILIC CENTERS, METHOD FOR THE PRODUCTION THEREOF AND THE USE OF THE COMPOUNDS AS MEDICINAL PRODUCTS, ACTIVE CARRIERS AND FOOD ADDITIVES
DE59304725D1 (en) 1992-07-22 1997-01-23 Hoechst Ag Crosslinked, nitrogen-containing vinyl copolymers, processes for their preparation and the use of these compounds
US5633344A (en) 1992-08-20 1997-05-27 E. I. Du Pont De Nemours & Company Crosslinked polymeric ammonium salts
US5451397A (en) 1992-12-21 1995-09-19 Rohm And Haas Company Bile acid sequestrant
JPH06321786A (en) * 1993-05-12 1994-11-22 Sekisui Chem Co Ltd Agent for inhibiting absorption of bile acid in enteric canal
US5487888A (en) 1993-05-20 1996-01-30 Geltex, Inc. Iron-binding polymers for oral administration
US5618530A (en) 1994-06-10 1997-04-08 Geltex Pharmaceuticals, Inc. Hydrophobic amine polymer sequestrant and method of cholesterol depletion
US5607669A (en) * 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
EP0706399A4 (en) 1993-06-02 1998-08-12 Geltex Pharma Inc Compositions and process for removing bile salts
US5496545A (en) 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5414068A (en) 1994-01-24 1995-05-09 Rohm And Haas Company Crosslinked anion exchange particles and method for producing the particles
TW474813B (en) 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624963A (en) * 1993-06-02 1997-04-29 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US5792749A (en) * 1997-01-09 1998-08-11 Virginia Commonwealth University Method and composition for lowering low density lipoprotein cholesterol

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9579343B2 (en) 1999-10-19 2017-02-28 Genzyme Corporation Direct compression polymer tablet core
US9931358B2 (en) 1999-10-19 2018-04-03 Genzyme Corporation Direct compression polymer tablet core
US8808738B2 (en) 2004-11-01 2014-08-19 Genzyme Corporation Aliphatic amine polymer salts for tableting
US9555056B2 (en) 2004-11-01 2017-01-31 Genzyme Corporation Aliphatic amine polymer salts for tableting
US9895315B2 (en) 2004-11-01 2018-02-20 Genzyme Corporation Aliphatic amine polymer salts for tableting
US8986669B2 (en) 2005-09-02 2015-03-24 Genzyme Corporation Method for removing phosphate and polymer used therefore
US9585911B2 (en) 2005-09-15 2017-03-07 Genzyme Corporation Sachet formulation for amine polymers
US8900560B2 (en) 2006-09-29 2014-12-02 Genzyme Corporation Amide dendrimer compositions
US9066972B2 (en) 2006-09-29 2015-06-30 Genzyme Corporation Amide dendrimer compositions
US8425887B2 (en) 2006-09-29 2013-04-23 Genzyme Corporation Amide dendrimer compositions
US8889738B2 (en) 2006-12-14 2014-11-18 Genzyme Corporation Amido-amine polymer compositions
US8163799B2 (en) 2006-12-14 2012-04-24 Genzyme Corporation Amido-amine polymer compositions
WO2009078956A1 (en) * 2007-12-14 2009-06-25 Genzyme Corporation Pharmaceutical compositions

Also Published As

Publication number Publication date
US20030086898A1 (en) 2003-05-08
KR20010013943A (en) 2001-02-26
CN1263468A (en) 2000-08-16
CA2294036C (en) 2007-08-21
HK1029920A1 (en) 2001-04-20
IL133434A (en) 2005-09-25
CN1211091C (en) 2005-07-20
EP0996454A1 (en) 2000-05-03
MY125874A (en) 2006-08-30
DE69818058T2 (en) 2004-07-08
AU7967598A (en) 1999-01-04
AU735260C (en) 2002-03-28
WO1998057652A1 (en) 1998-12-23
MXPA99011826A (en) 2002-07-02
US6423754B1 (en) 2002-07-23
EP0996454B1 (en) 2003-09-10
ATE249228T1 (en) 2003-09-15
JP2002516613A (en) 2002-06-04
JP4420143B2 (en) 2010-02-24
IL133434A0 (en) 2001-04-30
TW526063B (en) 2003-04-01
KR100567751B1 (en) 2006-04-05
NZ501719A (en) 2001-10-26
DE69818058D1 (en) 2003-10-16
AU735260B2 (en) 2001-07-05
CA2294036A1 (en) 1998-12-23

Similar Documents

Publication Publication Date Title
US6423754B1 (en) Method for treating hypercholesterolemia with polyallylamine polymers
US20080112918A1 (en) Method for treating gout and binding uric acid
US7229613B2 (en) Method for lowering serum glucose
CA2349620C (en) Use of aliphatic polyamines for reducing oxalate
AU698752C (en) Process for removing bile salts from a patient and alkylated compositions therefor
US20020187120A1 (en) Method for treating gout and reducing serum uric acid
US6566407B2 (en) Method for reducing oxalate
AU2002257145A1 (en) Method for lowering serum glucose
ZA200308063B (en) Method of lowering serum glucose.
US20020168333A1 (en) Method for improving vascular access in patients with vascular shunts
WO1998042355A1 (en) Phosphate-binding polymers combined with a calcium supplement for oral administration
EP1923064B1 (en) Use of amine polymer for lowering serum glucose

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION